Parexel just went into buying out and expending its portfolio in Regulatory approval processes. Though Quintile always had the first mover advantage and icon the smallest baby in the industry has matured quite fast. What i have observed is that PPD and Parexel have slight conservative approach compared to Quintiles and Icon in terms of their portfolio expansion and establishment in new territories. Like Quintiles new move in Biosimilars and RA therapy as such. Parexel went on to penetrate in the field of Biosimilars but more to watch from this CRO in terms of its strategic expansion in APAC, Middle east and Latin America
No comments:
Post a Comment